Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program

As previously announced, Valneva SE VALN said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions.
Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector COVID-19 vaccine (heterologous booster dose).
Related: Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study.
In Phase 3 Study COV-Compare study, neutralizing antibodies six months after the second dose of the primary vaccination with VLA2001 was non-inferior compared to the active comparator AZD1222, better known as AstraZeneca Plc's AZN Covishield.
The fold decline of neutralizing antibodies over six months after a second vaccination with VLA2001 was similar to the active comparator and less pronounced than other licensed COVID-19 vaccines.
Additionally, VLA2001-304 Phase 3 study in older adults showed that VLA2001 was well tolerated when administered as a two-dose or three-dose immunization.
In this age group, a two-dose vaccination with VLA2001 was inferior regarding geometric mean titers and seroconversion rates compared to younger adults.
After two doses, immunogenicity in older adults was at a level that could correlate with 60-70% vaccine efficacy against original SARS-CoV-2. A third dose further increased immunogenicity with a vaccine efficacy of over 90%.
Price Action: VALN shares traded flat at $12.29 on the last check Thursday.
Photo Via Wikimedia Commons

VALNValneva SE

$4.210.48%

Overview

AZNAstraZeneca PLC

$66.02-0.43%

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga